Syndax Pharmaceuticals (NASDAQ:SNDX) posted its quarterly earnings data on Monday. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08, Morningstar.com reports. Syndax Pharmaceuticals had a negative net margin of 3,190.51% and a negative return on equity of 80.35%. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million.
Syndax Pharmaceuticals stock opened at $4.86 on Tuesday. Syndax Pharmaceuticals has a 12 month low of $4.36 and a 12 month high of $15.20. The firm has a market cap of $119.58 million, a PE ratio of -1.68 and a beta of 2.63.
Several equities analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, July 12th. They set a “buy” rating and a $30.00 price objective on the stock. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Citigroup lowered their price objective on shares of Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, October 11th. Morgan Stanley cut shares of Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price objective on the stock. in a research report on Monday, October 29th. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.20.
Several institutional investors have recently bought and sold shares of SNDX. The Manufacturers Life Insurance Company boosted its holdings in Syndax Pharmaceuticals by 266.9% in the first quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after purchasing an additional 7,686 shares in the last quarter. Rhumbline Advisers bought a new stake in Syndax Pharmaceuticals in the second quarter worth $103,000. DRW Securities LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth $105,000. Bank of America Corp DE boosted its holdings in Syndax Pharmaceuticals by 1,382.0% in the second quarter. Bank of America Corp DE now owns 28,084 shares of the company’s stock worth $197,000 after purchasing an additional 26,189 shares in the last quarter. Finally, Spark Investment Management LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth $198,000. Institutional investors and hedge funds own 64.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Syndax Pharmaceuticals (SNDX) Issues Quarterly Earnings Results” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/06/syndax-pharmaceuticals-sndx-issues-quarterly-earnings-results.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.